Pharma industry wants Australia's price cut bill to be passed in November
This article was originally published in SRA
Executive Summary
Brendan Shaw, chief executive of R&D industry association Medicines Australia, has said that he hopes that Australia's medicines pricing bill – which targets savings of A$1.86 billion (US$1.86 billion) over five years – will be approved this month because one of its key provisions, namely the disclosure of the prices of the less innovative drugs in the F2 formulary, is expected to start on 1 December1.